Insilico Medicine Presents AI-Designed Cancer Drugs (IMAGE)

InSilico Medicine

Insilico Medicine Presents AI-Designed Cancer Drugs

Caption

At upcoming cancer conferences (ESMO, SITC, and SABCS), Insilico will present data on its novel QPCTL inhibitor for triple negative breast cancer and B-cell non-Hodgkin lymphoma; its novel ENPP1 inhibitor cancer immunotherapy for multiple tumor types; and its novel KAT6 inhibitor for the treatment of advanced ER+/HER2- breast cancer.

 

Credit

Insilico Medicine

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.